LPA rs10455872: What Your Genotype Means
The rs10455872 variant is a single-nucleotide polymorphism located within the LPA gene. It is strongly associated with elevated levels of Lipoprotein(a) in the blood, which is recognized as an independent risk factor for heart disease.
What each genotype means
Typical lipoprotein(a) levels
This genotype is considered the baseline or reference state for this variant. Research indicates that individuals with this profile typically do not have the genetic predisposition for elevated lipoprotein(a) levels associated with the G allele at this position.
This is the most common genotype in most populations, carried by the majority of individuals.
Increased lipoprotein(a) risk
Carrying one copy of the G allele is associated with higher plasma lipoprotein(a) concentrations compared to those without the variant. Elevated lipoprotein(a) is recognized as an independent risk factor for coronary artery disease and aortic valve stenosis, and you should discuss your cardiovascular health and lipid management with your clinician.
Carried by approximately 7-15% of people of European ancestry, with varying frequencies in other global populations.
Significantly elevated lipoprotein(a) risk
Carrying two copies of the G allele is strongly associated with significantly higher levels of lipoprotein(a) in the blood. This genetic profile is linked to an increased risk of premature cardiovascular disease and aortic valve calcification, and you should consult with a healthcare provider to discuss appropriate screening and heart health strategies.
This genotype is less common than the heterozygous state, occurring in a smaller percentage of the population.
Understanding the rs10455872 Variant
The rs10455872 variant is a specific genetic change, or single-nucleotide polymorphism (SNP), located on chromosome 6 within the LPA gene. In genetic terms, this variant involves a substitution where the nucleotide base adenine (A) is replaced by guanine (G). Because this SNP sits within the LPA gene, it can influence how the body produces and regulates a specific protein. Researchers track this variant because it serves as a reliable genetic marker for identifying individuals who may have naturally higher concentrations of Lipoprotein(a) circulating in their bloodstream. By studying this specific location in the human genome, scientists have been able to establish clear statistical links between this genetic signature and various cardiovascular health outcomes, making it a significant focus in modern genomic research.
The Role of the LPA Gene
The LPA gene provides the instructions for creating apolipoprotein(a), a protein that is a key component of Lipoprotein(a), or Lp(a). Lp(a) is a type of low-density lipoprotein particle that circulates in the blood. While the exact physiological function of Lp(a) is still being studied, high levels are widely recognized by the medical community as an independent risk factor for cardiovascular conditions, including coronary heart disease and aortic valve stenosis. The rs10455872 variant is considered a functional variant, meaning it is closely tied to the biological processes that determine how much Lp(a) is synthesized and released into the circulation. When the G allele is present, it is statistically associated with increased production or stability of these particles, which can lead to higher overall concentrations in the blood compared to individuals who carry the A allele.
Research and Cardiovascular Associations
Extensive research, including large-scale genome-wide association studies (GWAS), has consistently linked the rs10455872-G allele to elevated Lp(a) levels. This association is considered strong across multiple diverse populations. Clinical studies have observed that individuals carrying the G allele face a higher statistical risk for developing coronary heart disease and calcific aortic valve disease. The evidence suggests that the presence of this variant contributes to the development of atherosclerosis, the hardening and narrowing of the arteries. While the association is robust, it is important to note that genetic risk is only one piece of the puzzle. Cardiovascular health is influenced by a complex interplay of genetics, lifestyle factors, and other environmental variables. Researchers continue to investigate how this variant interacts with other genetic markers to better predict individual risk profiles.
Population Frequency
The frequency of the rs10455872 variant varies significantly across different ancestral groups. In European populations, the variant is relatively common, with an estimated frequency of approximately 7-15%. Because of this prevalence, it is a frequently studied marker in Western clinical research. However, the distribution of this SNP is not uniform globally, and researchers have noted that the impact of LPA variants on Lp(a) levels can be ancestry-specific. Understanding these population-level differences is crucial for researchers who aim to develop accurate risk assessment tools that are applicable to diverse groups of people. As genomic databases continue to grow, our understanding of how this variant is distributed across different global populations will become even more precise.
What This Information Means for You
Knowing your genotype for rs10455872 provides insight into your genetic predisposition for elevated Lipoprotein(a) levels, but it is not a medical diagnosis. Genetic information should never be used to self-diagnose or make independent decisions about your health or medication. If you are concerned about your cardiovascular health or your Lp(a) levels, the most effective step is to consult with a healthcare professional or a cardiologist. They can order appropriate blood tests to measure your actual Lp(a) levels and evaluate your overall cardiovascular risk profile based on your medical history, lifestyle, and other clinical markers. A doctor can help you interpret these results in the context of your total health and discuss whether any preventative measures or lifestyle adjustments are appropriate for your specific situation.
How common is this variant?
The rs10455872 variant is found in approximately 7-15% of European populations, though its frequency varies across different global ancestries.
Frequently asked questions
Is rs10455872 a diagnosis for heart disease?
No, this variant is not a diagnosis. It is a genetic marker associated with higher levels of Lipoprotein(a), which is a risk factor, but having the variant does not guarantee that you will develop heart disease.
Can I change my genotype for rs10455872?
No, your genotype is determined at conception and cannot be changed. However, you can work with a healthcare provider to manage your cardiovascular health through lifestyle changes and medical monitoring.
Should I get tested for this SNP?
Genetic testing for specific SNPs is generally not a routine clinical practice for the general public. If you have a family history of heart disease, discuss the appropriateness of Lp(a) blood testing with your doctor.
Does this variant affect how medications work?
While this variant is linked to Lp(a) levels, it is not a standard pharmacogenetic marker for drug dosing. Always consult your pharmacist or physician before making changes to any prescribed medication.
Sources & further reading
Educational information only, last refreshed 10/9/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs10455872?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in LPA
This variant in the LPA gene elevates serum lipoprotein(a) levels, significantly increasing the risk of coronary atherosclerosis and aortic stenosis.
Variant in the LPA gene locus associated with circulating lipoprotein(a) levels and cardiovascular healthspan.
Intronic splice-affecting variant in LPA leading to elevated plasma lipoprotein(a) concentrations and increased risk of aortic valve stenosis and coronary disease.
A splice-altering variant in LPA that lowers circulating lipoprotein(a) levels and is significantly associated with extended parental attained age and healthspan.
Intronic variant in LPA strongly associated with elevated circulating lipoprotein(a) levels and increased risk for coronary artery disease and aortic stenosis.
An LPA-locus variant identified as an independent genetic determinant of human healthspan and disease-free survival through modulated cardiovascular risk.